"Triazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Descriptor ID |
D014230
|
MeSH Number(s) |
D03.383.129.799
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Triazoles".
Below are MeSH descriptors whose meaning is more specific than "Triazoles".
This graph shows the total number of publications written about "Triazoles" by people in this website by year, and whether "Triazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2015 | 1 | 0 | 1 |
2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Triazoles" by people in Profiles.
-
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. Ann Oncol. 2016 05; 27(5):806-12.
-
Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status. Am J Med. 2016 Mar; 129(3):283-91.e5.
-
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat. 2008 Apr; 108(3):375-87.
-
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clin Breast Cancer. 2007 Jun; 7(8):608-18.
-
Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics. 2007; 25(4):329-42.